TILT Holdings Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Loans Receivable (Tables)

Loans Receivable (Tables)

12 Months Ended

Dec. 31, 2023

A breakdown of the loans receivable terms and balances are as follows:


Loans receivable	December 31, 2023		December 31, 2022
Teneo Fund SPVi LLC Note	$	5,622	$	5,911
Pharma EU, LLC Note		1,410		1,410
A&R Note		710		710
SSZ and Elev8 Note		1,002		1,002
Pure Hana Synergy Note		224		224
Little Beach Harvest Note		—		2,199
Total loans receivable	$	8,968	$	11,456
Less allowance for expected credit losses		(7,902)		(7,237)
Loans receivable, net of expected credit losses		1,066		4,219
Less current portion of loan receivable		—		(516)
Loans receivable, long-term	$	1,066	$	3,703

Schedule of analysis of credit quality of loans receivable

The following tables present an analysis of the credit quality of loans receivable, together with impairment losses recognized based on lifetime CECL reserves:


	As of December 31, 2023
Nature of collateral	Gross amounts		Loan losses		Net
Security interest in assets of counterparty	$	7,334		(6,268)	$	1,066
Third party guarantee		1,410		(1,410)		—
No collateral		224		(224)		—
Net loans receivable	$	8,968	$	(7,902)	$	1,066


	As of December 31, 2022
Nature of collateral	Gross amounts		Loan losses		Net
Security interest in assets of counterparty	$	9,822	$	(5,915)	$	3,907
Third party guarantee		1,410		(1,098)		312
No collateral		224		(224)		—
Net loans receivable	$	11,456	$	(7,237)	$	4,219